Optimizing postoperative inflammation in pediatric cataract surgery: Are intracameral steroids the way forward?

Pediatric cataracts continue to be a major cause of preventable childhood blindness worldwide. Pediatric cataract surgery is uniquely gratifying, with postoperative visual recovery often enabling children to recognize objects and faces for the first time. However, this rewarding outcome is counterbalanced by a substantial spectrum of postoperative challenges, including inflammation, elevated intraocular pressure (IOP), visual axis obscuration (VAO), and dynamic refractive changes, that collectively require long-term vigilance from the surgeon. The study by Authors S Agarwal et al.[1] has addressed an important aspect of reducing postoperative inflammation following pediatric cataract surgery. Pediatric eyes mount a markedly higher inflammatory response than adult eyes, owing to an immature blood–ocular barrier and enhanced uveal reactivity. This postoperative inflammation plays a pivotal role in the development of VAO, one of the most amblyogenic complications in growing children and a major determinant of visual prognosis. Corticosteroids are fundamental in postoperative care following cataract surgery. Traditionally, the regimen comprises an intraoperative subconjunctival steroid depot followed by an intensive tapered course of topical steroids, and, in selected cases, systemic therapy. Each route has inherent limitations, such as longer retention with subconjunctival injections, compliance-dependent issues with repeated application of topical medications, and potential adverse effects with systemic administration. These challenges are particularly relevant in younger children who rely entirely on caregivers for medication administration. Intracameral corticosteroids have therefore attracted interest as an intervention that ensures adequate anti-inflammatory effect in the immediate postoperative period while bypassing the variability of patient or caregiver compliance. Drugs including triamcinolone acetonide, dexamethasone and betamethasone have been employed for this purpose [Table 1], although most published evidence pertains to adult cataract surgery.[2,3] The initiative of Authors S Agarwal et al.[1] to evaluate and compare the anti-inflammatory performance of two intracameral steroids specifically in a pediatric cohort is timely and clinically relevant. Nonetheless, the study’s small sample size warrants caution in extrapolating results. Moreover, the administration of intensive postoperative topical betamethasone to both arms may have reduced the ability to detect meaningful differences attributable to the intracameral agents alone.Table 1: Steroids available for intracameral useThe role of corticosteroids in pediatric surgery must always be balanced against their potential to elevate IOP and precipitate secondary glaucoma, an entity often more refractory to management than primary congenital glaucoma.[4] Estimates suggest that between 25–75% of pediatric patients demonstrate steroid responsiveness, highlighting the wide interindividual variability in IOP reaction.[5] Systemic steroid exposure may additionally lead to hypothalamic–pituitary–adrenal axis suppression, adding a further layer of pediatric safety consideration. While intracameral steroid administration cannot replace the need for postoperative topical therapy, it may optimize early inflammation control, especially in young children, where adherence is unpredictable. However, the incorporation of intracameral steroids into routine pediatric cataract surgery must be accompanied by rigorous postoperative IOP monitoring and individualized adjustment of topical steroid regimens. The study by Authors S Agarwal et al.[1] provides useful insight into the evolving landscape of postoperative anti-inflammatory strategies in pediatric cataract surgery. Although the findings should be interpreted within the context of sample size and confounding topical therapy, the concept of intracameral steroid supplementation merits continued evaluation in larger, controlled cohorts. Optimizing the delicate balance between inflammation control and IOP safety remains central to achieving the best possible visual outcomes for children.